German company CureVac said on Friday that the vaccine against the COVID-19 The company’s first interim analysis has passed. But they are not yet ready to share information on how well the vaccine prevents infection. The shot could be cheaper and more accessible to low-income countries without vaccines.
The company said an independent data security audit committee found no security concerns. But the committee did not release any efficacy data, saying it was unclear how much protection the vaccine offered.
“This trial will continue to collect sufficient data to conduct a statistically significant performance analysis,” the company said in a statement.
The CureVac vaccine uses the same mRNA technology developed by Moderna and Pfizer-BioNTech. These vaccines are active in the United States and the European Union. and it has been proven to be highly effective. It raises hopes that CureVac may offer the same strong protection against Covid-19.
CureVac vaccines may have advantages over other mRNA vaccines. They can be stored in the refrigerator for at least 3 months at 41 degrees Fahrenheit. and can sit for 24 hours at room temperature before use.
In the initial formulation, Moderna and Pfizer-BioNTech vaccines It must be kept in a deep freezer. Both companies are modifying their formulas to make the vaccine more stable in warmer temperatures. This could expand its use in poorer countries where freezing is a challenge.
CureVac’s volumes may be cheaper than others Public Citizen Consumer Campaign Organization A report released Wednesday from researchers at Imperial College London assesses the cost of producing enough RNA vaccines to provide herd immunity in low- and middle-income countries. Researchers found that iIt cost $23 billion to build. Pfizer-BioNTech 8 billion doses, $9 billion for Moderna and just $4 billion for CureVac.
Last year, the company’s vaccines were effective when used on animals. in december They have launched a final clinical trial. It recruited 40,000 volunteers in 10 countries in Latin America and Europe. On Wednesday, CureVac said more information about the vaccine trial would arrive by the end of June.